Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
This security has been delisted
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Roche Holding AG ADR

WKN: 891106 / Symbol: RHHBY / Name: Roche / Stock / Pharmaceuticals / Large Cap /

€48.40
1.950%

6 3
6
3
Roche Bobois S.a.

WKN: A2JQRU / Name: Roche Bobois S.a. / Stock / ? /

?
-1.760%

0 0
0
0
Roche Holding AG

WKN: A4124Y / Name: Roche Holding / Stock / ? /

?
6.880%

1 0
1
0
Roche Holding AG

WKN: A40CGQ / Name: Roche Holding / Stock / ? /

?
3.250%

0 0
0
0
Roche Finance Europe B.v.

WKN: A3LEL7 / Name: Roche Finance Europe B.v. / Stock / ? /

€102.31
0.070%

0 0
0
0
Roche Finance Europe B.v.

WKN: A3LEL8 / Name: Roche Finance Europe B.v. / Stock / ? /

€101.78
0.070%

0 0
0
0
Roche Finance Europe B.v.

WKN: A3LRTS / Name: Roche Finance Europe B.v. / Stock / ? /

€101.67
0.000%

0 0
0
0
Roche Finance Europe B.v.

WKN: A3LRTT / Name: Roche Finance Europe B.v. / Stock / ? /

€101.66
0.160%

0 0
0
0
Roche Finance Europe B.v.

WKN: A3LX6K / Name: Roche Finance Europe B.v. / Stock / ? /

€102.62
0.030%

0 0
0
0
Roche Finance Europe B.v.

WKN: A3LX6L / Name: Roche Finance Europe B.v. / Stock / ? /

€95.64
0.160%

0 0
0
0
Roche Holdings Inc.

WKN: A3LVX8 / Name: Roche Holdings Inc. / Stock / ? /

€97.84
0.510%

0 0
0
0
Roche Holding AG

WKN: A424UK / Name: Roche Holding / Stock / ? /

€382.68
1.060%

2 0
2
0
Roche Aktie: cobas HDV-Test gestartetPhoto, wide shot, wide-angle lens, soft focus, Pharmaceutical company, sunset photo at golden hour, photo by Peter Lik: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-TIgKJfhK8q44RPNTTsL9npu7.png?st=2023-05-08T05%3A58%3A04Z&se=2023-05-08T07%3A58%3A04Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-08T02%3A36%3A56Z&ske=2023-05-09T02%3A36%3A56Z&sks=b&skv=2021-08-06&sig=BDDjRcmCPf%2BH//HSxRGZYByMqOKev8lx0/Dhvka/lXk%3D
Roche Aktie: cobas HDV-Test gestartet

Hepatitis D gilt als die gefährlichste Form der viralen Leberentzündung. Sie trifft nur Menschen,…

Der Beitrag Roche Aktie: cobas HDV-Test gestartet erschien zuerst auf kapitalmarktexperten.de.

Quel

TorstenPinkert 
0 14.07.26
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep MomentumPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by David Maisel: https://img.theapi.app/temp/0e9d087d-988e-4397-b7cf-6049e2776769.png
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum

Swiss pharma giant Roche Holding AG RHHBY reported sales of CHF 30.4 billion ($38.6 billion) in the first half of 2026, down 2% year over year due to the significant appreciation of the Swiss franc.

Zacks 
0 23.07.26
Rochefocauld
Account activated

21.01.21
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion

Roche RHHBY announced that the FDA has granted Priority Review to the company’s supplemental biologics license application (sBLA) seeking label expansion of Gazyva/Gazyvaro (obinutuzumab).

The sBLA

Zacks 
0 15.07.26
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik in erstem Halbjahr 2026 mit Umsatzwachstum von +6% zu konstanten Wechselkursen fort; -2% in CHF aufgrund deutlicher Aufwertung des Schweizer FrankensPhoto, wide shot, wide-angle lens, soft focus, Pharmaceutical company, sunset photo at golden hour, photo by Peter Lik: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-TIgKJfhK8q44RPNTTsL9npu7.png?st=2023-05-08T05%3A58%3A04Z&se=2023-05-08T07%3A58%3A04Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-08T02%3A36%3A56Z&ske=2023-05-09T02%3A36%3A56Z&sks=b&skv=2021-08-06&sig=BDDjRcmCPf%2BH//HSxRGZYByMqOKev8lx0/Dhvka/lXk%3D
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik in erstem Halbjahr 2026 mit Umsatzwachstum von +6% zu konstanten Wechselkursen fort; -2% in CHF aufgrund deutlicher Aufwertung des Schweizer Frankens
  • Konzernverkäufe stiegen in den ersten sechs Monaten um 6% zu konstanten Wechselkursen (CER1; in CHF ausgewiesen -2% und auf USD-Basis2 8%) aufgrund hoher Nachfrage nach innovativen Medikamenten
GlobeNewswire 
0 23.07.26